Skip to main navigation
logologo
  • About Us
    • Our Story
    • Message From CEO
    • Leadership Team
    • Board Members
    • Guiding Principles
    • Join Us
  • Our Science
    • Our Approach
    • Our Focus
      • MZL/FL
      • CLL
      • MS
    • Collaborate with Us
  • Our Products
  • Our Pipeline
    • Overview
    • Umbralisib
    • Ublituximab
    • TG-1501
    • TG-1701
    • TG-1801
  • Our Publications
  • Our Trials
    • Trial Information
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Stock Information
      • Historic Stock Lookup
    • SEC Filings & Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Events
    • IR & Media Contact
    • Management Team
    • Corporate Governance
    • FAQs
  • CAREERS
  • CONTACT US
  • Twitter
logo
Close
  • About Us
    • Our Story
    • Message From CEO
    • Leadership Team
    • Board Members
    • Guiding Principles
    • Join Us
  • Our Science
    • Our Approach
    • Our Focus
      • MZL/FL
      • CLL
      • MS
    • Collaborate with Us
  • Our Products
  • Our Pipeline
    • Overview
    • Umbralisib
    • Ublituximab
    • TG-1501
    • TG-1701
    • TG-1801
  • Our Publications
  • Our Trials
    • Trial Information
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Stock Information
      • Historic Stock Lookup
    • SEC Filings & Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Events
    • IR & Media Contact
    • Management Team
    • Corporate Governance
    • FAQs
Banner Image Banner Image

Investors
& Media

Event Details

« Back

First Quarter 2017 Earnings Results

May 05, 2017 at 8:30 AM EDT

Listen to webcast
Email Alerts
RSS News Feeds
Print Page
Share facebook linkedin twitter
Search
Component-5-–-2

Email Us 1-877-575-TGTX (8489)

TG Therapeutics © . All rights reserved.

  • Join us
  • Contact Us
  • Privacy Policy
  • Terms of Use